Introduction
Post-traumatic stress disorder (PTSD) affects approximately 13 million Americans at any given time, and existing treatments leave roughly 40-60% of patients with significant residual symptoms. MDMA-assisted therapy represents a fundamentally different approach: rather than daily medication, it uses a small number of MDMA sessions combined with psychotherapy to catalyze the processing of traumatic memories. The results from Phase 2 and Phase 3 clinical trials have been among the most dramatic in the history of psychiatric treatment, though the path to regulatory approval has proven complex.
The MAPS Journey
The story of MDMA therapy is inseparable from the Multidisciplinary Association for Psychedelic Studies (MAPS), founded by Rick Doblin in 1986 with the explicit goal of making MDMA a legal medicine. After MDMA was emergency-scheduled by the DEA in 1985 -- over the objections of the DEA's own administrative law judge -- Doblin spent decades navigating regulatory pathways, raising funds, and building the scientific case for clinical research.
The first FDA-approved Phase 1 safety study began in 1994 under the direction of Charles Grob at UCLA. MAPS-sponsored Phase 2 trials began in 2004, conducted by Michael Mithoefer, a psychiatrist in Charleston, South Carolina, and ran across multiple sites through 2017.